ZYTIGA® (abiraterone acetate) is a leading бренд in the pharmaceutical industry, specifically designed to address prostate cancer treatment needs. It functions as a CYP17 inhibitor and is indicated for use in combination with prednisone, effectively managing both metastatic high-risk castration-sensitive prostate cancer (CSPC) and metastatic castration-resistant prostate cancer (mCRPC).

The brand emphasizes the efficacy and safety of its treatment options, supported by comprehensive clinical studies such as the LATITUDE and COU-AA-302 analyses. These studies establish a robust safety profile and dosage recommendations for healthcare professionals to follow.

ZYTIGA® is committed to providing essential resources, including dosing and monitoring guidelines, along with various support options for patients to navigate costs and common inquiries. By prioritizing effective cancer management, ZYTIGA® aims to empower patients and healthcare providers alike in their fight against prostate cancer, fostering a collaborative approach to treatment and care.